Abstract: An antibody having a higher function targeting a CD73 antigen, and more specifically, an antibody for cancer treatment having a higher activity. The antibody or a human-type antibody derivative that has a binding activity to a CD73 antigen and activates T cells having a toxic activity to cancer cells, and includes complementarity determining regions of any combination of heavy and light chains each having a specific amino acid sequence.

Abstract: A peptide vaccine complexed so that the peptide vaccine can be delivered specifically to the surface of specific immune cells and a method for delivering a peptide vaccine specifically to the surface of specific immune cells. The peptide vaccine is combined with an IgG binding peptide capable of binding to an IgG that is an agonist against molecules on the surface of specific immune cells such as dendritic cells.

Abstract: Provided herein are non-invasive methods and biomarkers that identify progression and clonal evolution of plasma cell dyscrasias. Also provided are materials and methods for the diagnosis, prognosis, staging, and monitoring of plasma cell dyscrasias based on the presence of the biomarkers in a blood biopsy, as well as methods for monitoring the progression of a plasma cell dyscrasia, determining the efficacy of a therapeutic agent, determining a targeted therapy related to a plasma cell dyscrasia, and/or treating a plasma cell dyscrasia. The methods provided herein provide several advantages over invasive biopsies.

Abstract: Provided herein are non-invasive methods and biomarkers that identify progression and clonal evolution of plasma cell dyscrasias. Also provided are materials and methods for the diagnosis, prognosis, staging, and monitoring of plasma cell dyscrasias based on the presence of the bio markers in a blood biopsy, as well as methods for monitoring the progression of a plasma cell dyscrasia, determining the efficacy of a therapeutic agent, determining a targeted therapy related to a plasma cell dyscrasia, and/or treating a plasma cell dyscrasia. The methods provided herein provide several advantages over invasive biopsies.

Abstract: A method of analyzing eukaryotic cells includes conducting a reaction using an antibody against a surface antigen of a cell to be analyzed for genetic abnormality or a cell not to be analyzed for the abnormality, to distinguish cells to be analyzed for the abnormality, subjecting the cells to permeation treatment, and to immobilization treatment after at least one of the antigen-antibody reaction and permeation treatment steps, conducting fluorescence in situ hybridization using at least one nucleic acid probe, each probe having a different fluorescent label and specifically binding to a genetic sequence to be detected, obtaining fluorescence signals from the probes in the cells using a three-dimensional image analysis method, and determining whether any cells have the abnormality by analyzing the cells distinguished to be analyzed for the abnormality, at least one signal count of the fluorescence signals, the signal count corresponding respectively to the probe.

Abstract: Provided herein are non-invasive methods and biomarkers that identify progression and clonal evolution of plasma cell dyscrasias. Also provided are materials and methods for the diagnosis, prognosis, staging, and monitoring of plasma cell dyscrasias based on the presence of the bio markers in a blood biopsy, as well as methods for monitoring the progression of a plasma cell dyscrasia, determining the efficacy of a therapeutic agent, determining a targeted therapy related to a plasma cell dyscrasia, and/or treating a plasma cell dyscrasia. The methods provided herein provide several advantages over invasive biopsies.

Abstract: The present invention relates to Li-Ni composite oxide particles that exhibit a high initial discharge capacity and are excellent in thermal stability when used as a positive electrode active substance for non-aqueous electrolyte secondary batteries, and a process for producing the Li-Nicomposite oxide particles. The Li-Ni composite oxide particles of the present invention have a composition of LixNi1?y?a?bCoyM1aM2bO2 wherein x, y, a and b represent 1.00?x?1.10; 0<y?0.25; 0<a?0.25; and 0?b?0.10, respectively; M1 is at least one element selected from the group consisting of Al and Mn; and M2 is at least one element selected from the group consisting of Zr and Mg, in which a product of a metal occupancy (%) of lithium sites of the Li-Ni composite oxide as determined by Rietveld analysis of X-ray diffraction thereof and a crystallite size (nm) of the Li-Ni composite oxide as determined by the Rietveld analysis is not less than 700 and not more than 1400.

Abstract: The present invention relates to Li—Ni composite oxide particles having a composition of Lix(NiyCo2(1-y)/5Mn3(1-y)/5)1-zMzO2 wherein x, y and z represent 1.00?x?1.10; 0.65<y<0.82; and 0?z<0.05, respectively; and M is at least one element selected from the group consisting of Al, Zr and Mg. The Li—Ni composite oxide particles of the present invention exhibit a high initial discharge capacity and are excellent in first-cycle charge/discharge efficiency when used as a positive electrode active substance for non-aqueous electrolyte secondary batteries.

Abstract: The present invention relates to Li—Ni composite oxide particles that exhibit a high initial discharge capacity and are excellent in thermal stability when used as a positive electrode active substance for non-aqueous electrolyte secondary batteries, and a process for producing the Li—Ni composite oxide particles. The Li—Ni composite oxide particles of the present invention have a composition of LixNi1-y-a-bCoyM1aM2bO2 wherein x, y, a and b represent 1.00?x?1.10; 0<y?0.25; 0<a?0.25; and 0?b?0.10, respectively; M1 is at least one element selected from the group consisting of Al and Mn; and M2 is at least one element selected from the group consisting of Zr and Mg, in which a product of a metal occupancy (%) of lithium sites of the Li—Ni composite oxide as determined by Rietveld analysis of X-ray diffraction thereof and a crystallite size (nm) of the Li—Ni composite oxide as determined by the Rietveld analysis is not less than 700 and not more than 1400.

Abstract: A dehydrogenation catalyst composition for use in preparing an alkenyl aromatic compound by dehydrogenation of an alkyl aromatic compound, a method for preparing the catalyst, and a process for using the catalyst in a dehydrogenation reaction. Carbon dioxide (CO2) is present in the reaction in a molar ratio of 0.015 to 0.20 based on an aromatic compound in a material gas. The catalyst further includes an iron compound, an alkali metal, and about 13 to about 60 wt % of a rare earth element calculated as an oxide.

Abstract: The present invention relates to ferric phosphate hydrate particles for use as a precursor of olivine type lithium iron phosphate particles, wherein the ferric phosphate hydrate particles exhibit at least one crystal structure selected from the group consisting of a strengite crystal structure and a meta-strengite (phosphosiderite) crystal structure, and have a sodium (Na) content of not more than 100 ppm and a molar ratio of phosphorus to iron (phosphorus/iron) of not less than 0.9 and not more than 1.1. The ferric phosphate hydrate particles according to the present invention are suitable as a precursor of olivine type lithium iron phosphate particles for a positive electrode substance of non-aqueous electrolyte secondary batteries, and are in the form of fine particles and have a very small content of impurities.

Abstract: The present invention relates to a positive electrode active substance for non-aqueous electrolyte secondary batteries which comprises particles comprising a polyanionic compound and carbon, and a lipophilic treatment agent with which the respective particles are coated, wherein the positive electrode active substance has an average particle diameter of 1 to 50 ?m. The positive electrode active substance preferably has an oil absorption of not more than 20 mL/100 g. The positive electrode active substance according to the present invention exhibits a good compatibility with a resin and is excellent in packing property and dispersibility in the resin, and therefore can provide an electrode sheet in which the positive electrode active substance is filled with a high packing density.

Abstract: The present invention relates to a method for analyzing genetically abnormal cells including (a) preparing a cell sample containing eukaryotic cells, (b) conducting an antigen-antibody reaction to cells contained in the cell sample using antibodies which specifically bind to a molecule existing on the cell surface of eukaryotic cells after (a), (c) subjecting the cells contained in the cell sample to a permeation treatment after (b), (d) subjecting the cells contained in the cell sample to an immobilization treatment after (b), (e) conducting FISH to the cells contained in the cell sample using nucleic acid probes after (d), (f) analyzing fluorescence signals from the nucleic acid probes in the cells contained in the cell sample using a three-dimensional image analysis method after (e), and (g) determining whether the cells contained in the cell sample are genetically abnormal cells or not based on the results of (b) and (f).

Abstract: A dehydrogenation catalyst composition for use in preparing an alkenyl aromatic compound by dehydrogenation of an alkyl aromatic compound, a method for preparing the catalyst, and a process for using the catalyst in a dehydrogenation reaction. Carbon dioxide (CO2) is present in the reaction in a molar ratio of 0.015 to 0.20 based on an aromatic compound in a material gas. The catalyst further includes an iron compound, an alkali metal, and about 13 to about 60 wt % of a rare earth element calculated as an oxide.

Abstract: The object of the present invention is to provide the catalyst used in a process for preparation of alkenylaromatic compounds by dehydrogenating alkyl aromatic compounds by means of steam as a diluent, wherein the catalyst prevents the block and corrosion caused by the alkali metal component migrated from the catalyst, and the process for producing same, and the dehydrogenation method using it. The solid catalyst which has the high redox ability and comprises no alkali metal component migrated from the catalyst in the presence of steam with high temperature is used.

Abstract: The present invention relates to a process for producing lithium iron phosphate particles having an olivine type structure, comprising a first step of mixing an iron oxide or an iron oxide hydroxide as an iron raw material which comprises at least one element selected from the group consisting of Na, Mg, Al, Si, Cr, Mn and Ni in an amount of 0.1 to 2 mol % for each element based on Fe, and a carbon element C in an amount of 5 to 10 mol % based on Fe, and has a content of Fe2+ of not more than 40 mol % based on an amount of Fe and an average primary particle diameter of 5 to 300 nm, with a lithium raw material and a phosphorus raw material; a second step of controlling agglomerates diameter in the resulting mixture is 0.3 to 5.0 ?m; and a third step of sintering the mixture obtained in the second step in an inert gas or reducing gas atmosphere having an oxygen concentration of not more than 0.1% at a temperature of 250 to 750° C.

Abstract: The fine barium titanate particles of the present invention have an average primary particle diameter of from 10 nm to less than 20 nm, a sphericity of 1.00 to 1.18, and a ratio of an average secondary particle diameter to the average primary particle diameter of 0.7 to 6.0. The fine barium titanate particles of the present invention can exhibit a small behavior particle diameter and can be readily monodispersed notwithstanding very fine particles, and as a result, can be suitably used as various dielectric materials because the particles are free from aggregation therebetween and have an excellent dispersibility.

Abstract: A high cerium-containing dehydrogenation catalyst of alkyl aromatic compounds used in industrial scale, including iron oxide and potassium oxide, having improved physical strength of catalyst pellets, and a method for producing the catalyst, and the dehydrogenation method using the catalyst are disclosed. In producing high cerium-containing pellets by using a dehydrogenation catalyst including iron oxide and potassium oxide, cerium carbonate hydroxide or a mixture of cerium carbonate hydroxide and other cerium compounds is used as a cerium source to produce catalytic pellets having improved physical strength.

Abstract: Spherical tetragonal barium titanate particles of the present invention have a perovskite crystal structure, an average particle diameter of 0.05 to 0.5 ?m, a particle size distribution ?g of not less than 0.70, and a ratio of Ba to Ti of 0.99:1 to 1.01:1. The spherical tetragonal barium titanate particles exhibit an excellent dispersibility as well as a high denseness, a high purity and excellent permittivity properties.

Abstract: A lactoferrin hydrolysate mixture or lactoferrin partial peptide that can be obtained by hydrolyzing lactoferrin with a hydrolytic enzyme and has an action of enhancing cytotoxic activity of an antibody drug in an antibody therapy of cancer is used as an active ingredient of a drug for enhancing cytotoxic activity of an antibody drug in an antibody therapy of cancer.